Methods: We performed a meta-analysis using MEDLINE Vadimezan mw and EMBASE search and reviews of article bibliographies and abstracts from recent scientific meetings.

Criteria for acute HCV was HCV-RNA positivity or anti-HCV seroconversion within six months since last negative tests, except one where twelve months was used. Included studies had at least ten adult HIV+/acute HCV patients who initiated P/R for 24 to 48 weeks. Data was insufficient for separate analysis for SVR by treatment duration. We excluded retreated patients. Random effects model was used for meta-analysis, with results expressed as pooled probability. Results: Twelve studies met the inclusion criteria and were included in the current analysis. Pooled Selleck Fulvestrant SVR was 71.4% (323/450) (Figure). RVR was 47.4% (93/196), and EVR was 82.8% (221/283). Probability of SVR was 93.1% (77/82) in patients who obtained RVR, 85.9% (150/168) if EVR+. Conclusion: P/R for 24 to 48 weeks is effective in the treatment of acute HCV in HIV

co-infected patients with SVR over 70% and over 90% in those with RVR and close to 90% for those with EVR. P/R can be a reasonable option for patients who do not have access to newer but more expensive anti-HCV therapy. SVR for all studies and pooled. Disclosures: Walid S. Ayoub – Advisory Committees or Review Panels: Gilead Mindie H. Nguyen – Advisory Committees or Review Panels: Bristol-Myers Squibb, Bayer AG, Thalidomide Gilead, Novartis, Onyx; Consulting: Gilead Sciences, Inc.; Grant/Research Support: Gilead Sciences, Inc., Bristol-Myers Squibb, Novartis Pharmaceuticals, Roche Pharma AG, Idenix, Hologic, ISIS The following people have nothing to disclose: Bing Zhang, Benjamin Yip, Nghia H. Nguyen, Brittany E. Yee, Glen A. Lutchman Background and Aims: A single nucleotide polymorphism (SNP) rs368234815 (TT/G) within a newly discovered type III interferon, interferon lambda 4 (IFNL4) located upstream of

interleukin-28B (IL-28B), have been reported to strongly affect anti-viral therapy for chronic hepatitis C virus (HCV) infection in African and Caucasian populations compared to previously reported IL-28B SNPs, rs12979860 and rs8099917. This study was aimed to compare the predictability of IFNL4/IL-28B polymorphisms for viral response among HCV patients in Japanese population. Methods: We analyzed the haplotype structure of IFNL4/IL-28B consisting of three SNPs (rs12979860, rs368234815, and rs8099917) in 4,630 Japanese chronic hepatitis C patients and 1,122 healthy controls, and then compared their impact on treatment outcome to pegylated-in-terferon (PEG-IFN) plus ribavirin (RBV) combined therapy in 903 HCV-1b infected patients. Next, associations between early viral response and genotypes were compared among the SNPs in 479 patients infected with HCV genotype 1b.